|
WO2015023902A2
|
|
Improving visual function associated with impaired dark adaptation and/or impaired low luminance vision
|
|
NZ629267A
|
|
Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
|
|
US2015038582A1
|
|
Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
|
|
AU2012201879A1
|
|
Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
|
|
JP2012092145A
|
|
Composition for visual acuity amelioration through photodynamic therapy of eye
|
|
MX2013008175A
|
|
Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof.
|
|
AU2011256899A1
|
|
Photodynamic therapy for the treatment of acne
|
|
AU2011235979A1
|
|
Drug delivery methods, structures, and compositions for nasolacrimal system
|
|
AU2011235978A1
|
|
Nasolacrimal drainage system implants for drug therapy
|
|
CN102939081A
|
|
Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
|
|
EP2376019A1
|
|
Substance delivering punctum implants and methods
|
|
CA2747219A1
|
|
Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature
|
|
CA2774168A1
|
|
Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
|
|
AU2009215897A1
|
|
Lacrimal implants and related methods
|
|
AU2008300013A1
|
|
Drug cores for sustained release of therapeutic agents
|
|
AU2008296872A1
|
|
Lacrimal implants and related methods
|
|
NZ577948A
|
|
Drug delivery implants for inhibition of optical defects
|
|
AU2007237228A1
|
|
Cancer associated protein kinases and their uses
|
|
WO2008052350A1
|
|
Photodynamic therapy for the treatment of hidradenitis suppurativa
|
|
WO2008058034A1
|
|
Methods of treating dermatological disorders or conditions
|
